Q3 Earnings Estimate for CorMedix Issued By Leerink Partnrs

Key Points

• Analysts at Leerink Partners estimate CorMedix will post a Q3 2025 EPS of $0.57, while the full-year earnings estimate is a loss of ($0.32) per share.
• CorMedix experienced significant growth with a revenue increase of 4830.1% year-over-year, reporting $39.74 million in revenue and beating consensus estimates.
• Institutional investors have notably increased their holdings, with Marshall Wace LLP boosting its position by over 1000% in the second quarter.

CorMedix Inc (NASDAQ:CRMD - Free Report) - Analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for CorMedix in a research note issued on Tuesday, September 23rd. Leerink Partnrs analyst R. Ruiz expects that the company will post earnings per share of $0.57 for the quarter. The consensus estimate for CorMedix's current full-year earnings is ($0.32) per share. Leerink Partnrs also issued estimates for CorMedix's Q4 2025 earnings at $0.75 EPS, FY2025 earnings at $1.91 EPS, FY2026 earnings at $2.91 EPS, FY2027 earnings at $3.06 EPS and FY2028 earnings at $3.50 EPS.

A number of other equities research analysts have also recently commented on CRMD. JMP Securities reissued a "market outperform" rating and issued a $22.00 price objective on shares of CorMedix in a research note on Tuesday, September 9th. Needham & Company LLC lifted their price target on shares of CorMedix from $15.00 to $20.00 and gave the company a "buy" rating in a research report on Tuesday, June 24th. Wall Street Zen upgraded shares of CorMedix from a "buy" rating to a "strong-buy" rating in a report on Saturday, September 13th. D Boral Capital cut shares of CorMedix from a "strong-buy" rating to a "hold" rating in a report on Monday, June 30th. Finally, D. Boral Capital cut shares of CorMedix from a "buy" rating to a "hold" rating in a report on Monday, June 30th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $18.00.

CorMedix Price Performance

Shares of CRMD opened at $11.24 on Thursday. CorMedix has a one year low of $5.60 and a one year high of $17.43. The stock has a 50-day moving average of $12.34 and a 200-day moving average of $11.29. The company has a market cap of $877.39 million, a PE ratio of 14.99 and a beta of 1.76.

CorMedix (NASDAQ:CRMD - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.20 by $0.08. The company had revenue of $39.74 million during the quarter, compared to the consensus estimate of $29.88 million. CorMedix had a return on equity of 42.73% and a net margin of 42.11%.The firm's revenue for the quarter was up 4830.1% compared to the same quarter last year. During the same period last year, the business posted ($0.25) EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CRMD. Marshall Wace LLP boosted its holdings in shares of CorMedix by 1,019.2% in the 2nd quarter. Marshall Wace LLP now owns 2,579,976 shares of the company's stock worth $31,785,000 after buying an additional 2,349,451 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in CorMedix in the second quarter valued at approximately $5,115,000. Nuveen LLC purchased a new position in CorMedix in the first quarter valued at approximately $1,692,000. Vanguard Group Inc. lifted its stake in CorMedix by 7.9% in the first quarter. Vanguard Group Inc. now owns 3,646,551 shares of the company's stock valued at $22,463,000 after purchasing an additional 268,360 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in CorMedix by 1,070.3% in the first quarter. Invesco Ltd. now owns 289,110 shares of the company's stock valued at $1,781,000 after purchasing an additional 264,407 shares during the last quarter. Hedge funds and other institutional investors own 34.18% of the company's stock.

Insider Activity

In related news, insider Kaufman Beth Zelnick sold 50,000 shares of the business's stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $13.41, for a total transaction of $670,500.00. Following the transaction, the insider directly owned 180,418 shares in the company, valued at approximately $2,419,405.38. The trade was a 21.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Elizabeth Hurlburt sold 41,121 shares of the business's stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $13.08, for a total transaction of $537,862.68. Following the transaction, the chief operating officer owned 176,990 shares in the company, valued at approximately $2,315,029.20. This trade represents a 18.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 163,997 shares of company stock valued at $2,163,617 in the last three months. 5.30% of the stock is owned by company insiders.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.